Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialTUTT, Andrew; ROBSON, Mark; WARDLEY, Andrew et al.Lancet (British edition). 2010, Vol 376, Num 9737, pp 235-244, issn 0140-6736, 10 p.Article

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y₁₂ receptor antagonist, compared with clopidogrel in patients with acute coronary syndromesSTOREY, Robert F; HUSTED, Steen; CANNON, Christopher P et al.Journal of the American College of Cardiology. 2007, Vol 50, Num 19, pp 1852-1856, issn 0735-1097, 5 p.Article

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialAUDEH, M. William; CARMICHAEL, James; LU, n et al.Lancet (British edition). 2010, Vol 376, Num 9737, pp 245-251, issn 0140-6736, 7 p.Article

Analgesic efficacy of the cyclooxygenase-inhibiting nitric oxide donor AZD3582 in postoperative dental pain : Comparison with naproxen and rofecoxib in two randomized, double-blind, placebo-controlled studiesHILL, C. Michael; SINDET-PEDERSON, Steen; SVENSSON, Ola et al.Clinical therapeutics. 2006, Vol 28, Num 9, pp 1279-1295, issn 0149-2918, 17 p.Article